medigraphic.com
ISSN 1561-2945 (Print)

2012, Number 3

<< Back Next >>

Revista Cubana de Cirugía 2012; 51 (3)

Update on treatment of stage IIIA non-small cell lung cancer with N2 disease

García RME, Armas PBA, Armas MK

Language: Spanish
References: 72
Page:
PDF size: 98.30 Kb.


ABSTRACT

The patients suffering stage IIIA non-small cell lung cancer with N2 ganglionic diseases are common and considered as an heterogeneous group by many physicians. Their treatment arouses controversies. For the purpose of making an updated literature review on this topic and defining the treatment options for these patients on this stage III, a number of full articles and of abstracts was searched on several database (Medline, Cochrane, Pubmed, Ebsco, Hinari). To this end, the End Note locator was used with the following English words and their respective Spanish translations: lung cancer, stage IIIa, radiotherapy, chemotherapy, adjuvant treatment, surgery, lymphoadenectomy. The optimal management of patients classified as stage IIIA (N2) remains one of the most controversial areas in the care of patients who suffered non-small cell lung cancer, probably due to the wide pathological variations occurring in this stage. Therefore, it is accepted to apply surgical treatment as first option in those patients presenting with minimal N2 disease, and on the other hand, the definite treatment with chemoradiotherapy or presurgical induction treatment in selected cases.


REFERENCES

  1. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg. 1978;76:833-9.

  2. Martini N. Mediastinal lymph node dissection for lung cancer. The Memorial experiencia. Chest Surg Clin N Am. 1995;5:189-203.

  3. Pearson FG, Delarue WC, Ilves R, Tood TRJ, Cooper JD. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg. 1980;80:390-9.

  4. Rami Porta, R. Nueva clasificación TNM del cáncer de pulmón. Arch Bronconeumol. 2009;45(4):159-61.

  5. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD. Disponible en: http://seer.cancer.gov/csr/1975_2009_pops09/

  6. Vest MT, Tanoue L, Soulos PR, Kim AW, Detterbeck F, Morgemsztern D, et al. Thoroughness of Mediastinal Staging in Stage IIIA Non-small Cell Lung Cancer. J Thorac Oncol. 2012 Jan;7(1):188-95.

  7. Ruckdeschel JC. Combined modality therapy of non-small cell lung cancer. Seminar Oncol. 1997;24:429-39.

  8. John Borrie. Lung Cancer: Surgery and Survival (The Book Forum). 1st. ed. NewYork.1965; Appleton-Century-Crofts, Division of Meredith Publishing. pp 202.

  9. Nohl-Osler HC. An investigation of the anatomy of the lymphatic drainage of the lungs as shown by the lymphatic spread of bronchial carcinoma. Ann R Coll Surg Engl 1972;51:157-76.

  10. Cahan WG, Watson WL, Pool JL. Radical pneumonectomy. J Thorac Cardiovasc Surg. 1951;22:449-73.

  11. Cahan WG. Radical lobectomy. J Thorac Cardiovasc Surg 1960;39:555-72.

  12. Sakakura N, Mori S, Okuda K, Fukui T, Hatooka S, Shinoda M et al. Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures. Ann Thorac Surg. 2008;86:1084-91.

  13. Little AG, Rush VW, Bonner JA. Patterns of Surgical Care of Lung Cancer Patients. Ann Thorac Surg 2005;80:2051-6.

  14. Riquet M, Assouad J, Bagan P, Foucault C, Le Pimpec F, Dujon A, et al. Skip Mediastinal Lymph Node Metastasis and Lung Cancer: A particular N2 Subgroups with a Better Prognosis. Ann Thorac Surg. 2005;79:225-33.

  15. Whitson BA, Groth SS, Maddaus MA. Recommendations for optimal use of imaging studies to clinically stage mediastinal lymph nodes in non-small-cell lung cancer patients. Lung Cancer. 2008;61:177-85.

  16. Detterbeck F. What to do with "Surprise" N2? Intraoperative Management of Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2008;3(3):289-302.

  17. Verhagen AF, Schoenmakersa MCJ, Barendregtb W, Smitc H, van Bovend WJ, Looijene M, et al. Completeness of lung cancer surgery: is mediastinal dissection common practice? Eur J Cardiothorac Surg. 2012;41(4):839-40.

  18. Saínz Menéndez B. Tumores benignos y malignos del pulmón: Clasificación. Diagnóstico. Tratamiento. Rev Cubana Cir;45(3-4): Disponible en:http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S003474932006000300021&lng=es

  19. Detterbeck FC, Boffa D J, Tanoue LT, Wilson LD. Details and Difficulties Regarding the New Lung Cancer Staging System. Chest 2010;137;1172-80.

  20. Rush WV, Crowley J, Giroux DJ, De Leyn C. The IASLC Lung Cancer Staging Project: proposals for revision of the N descriptions in the forth coming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol. 2007;2:603-12.

  21. Xu Y, Shentu Y, Zheng M, Guo M. The clinical value of routine preoperative surgical staging to mediastinal lymph nodes on lung cancer. Zhongguo Fei Ai Za Zhi. 2010;13(6):624-7.

  22. Mountain CF, Dressler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718-23.

  23. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260-71.

  24. Wang YX, Sun YE, Li XH, Wang ZB, Tong XY, Liu YL. Comparative study on molecular staging of lymph nodes in non-small cell lung cancer patients. Ai Zheng. 2009;28(3):318-22.

  25. Detterbeck FC, Boffa D J, Tanoue LT, Wilson LD. Anatomy, Biology and Concepts, Pertaining to Lung Cancer Stage Classification. J Thorac Oncol. 2009;4:437-43.

  26. Hanagiri T, Takenaka M, Oka S, Shigematsu Y, Nagata Y, Shimokawa H, et al. Clinical significance in the number of involved lymph nodes in patients that underwent surgery for pathological stage III-N2 non-small cell lung cancer. J Cardiothorac Surg. 2011; 6:144-50.

  27. Misthos P, Sepsas E, Kokotsakis J, Skottis I, Lioulias A. The significance of one-station N2 disease in the prognosis of patients with non-small-cell lung cancer. Ann Thorac Surg. 2008;86:1626-31.

  28. Muehling B. Comparison of Clinical and Surgical-Pathological Staging in IIIA Non-Small Cell Lung Cancer Patients Comparison of Clinical and Surgical Pathological Staging in IIIA Non-Small Cell Lung Cancer Patients. Ann Surg Oncol. (2012)19:89-93.

  29. Brichkov I, Keller SM. Intraoperative staging and surgical management of stage IIIA/N2 non-small cell lung cancer. Thorac Surg Clin. 2008;18(4):381-91.

  30. Sakao Y, Hideaki H, Yamamoto M, Yamazaki A, Ou S, Shiomi K, et al. The spread of metastatic lymph nodes to the mediastinum from left upper lobe cancer: result of superior mediastinal nodal dissection through a median sternotomy. Eur J Cardiothorac Surg. 2006;30:543-7.

  31. Naruke T, Tsuchiya R, Hondo H, Nakayama H, Asamura H. Lymph node sampling in lung cancer: How should it be done? Eu Journal Cardio-Thoracic Surgery. 1993;16(supl 1):S17-S24.

  32. Schinkel C, Mueller C, Reinmiedi J, Hoffmann H, Zimmer S, Dienemann H,et al. Mediastinal lymph node infiltration in non-small-cell lung cancer and its role in curative surgery. Scand Cardiovasc. 1999;J33:286-8.

  33. Meacci E, Cesareo A, Cusumano G, Lococo F. Surgery for patients with persistent pathological N2 IIIA stage in non-small-cell lung cancer after induction radio-chemotherapy: the microscopic seed of doubt. European Journal of Surgery. 2011;40(3):656-63.

  34. Friedel G, Budach W, Dippon J. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol. 2010;28(6):942-8.

  35. Uehara H, Sakao Y, Mun M, Nakagawa K, Nishio M, Ishikawa Y, et al. Prognostic value and significance of subcarinal and superior mediastinal lymph node metastasis in lower lobe tumours. Eur J Cardiothorac Surg. 2010;38(4):498-502.

  36. Aokage K, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Subcarinal lymph node in upper lobe non-small cell lung cancer patients: is selective lymph node dissection valid? Lung Cancer. 2010;70(2):163-7.

  37. Caglar HB, Baldini EH, Othus M, Rabin MS, Bueno R, Sugarbaker DJ, et al. Outcomes of patients with stage III non small-cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer. 2009; 115:4156-66.

  38. Albain KS, Swann RS, Rush VW, Turrisi AT.Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomized controlled trial. Lancet. 2009;374(9687):379-86.

  39. Riquet M, Bagan P, Le Pimpec Barthes F. Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases, Ann Thorac Surg 2007;84:1818-24.

  40. Zhang GQ, Han F, Gao SL Pang ZL. Two patterns of mediastinal lymph node resection for non-small cell lung cancer of stage IIIA: survival analysis of 219 cases. Chinese Journal of Cancer. 2007; 26(5):519-23.

  41. Esteban E, De Sande JL, Villanueva N, Corral N. Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical loco regional treatment for patients with stage III non-small-cell lung cancer (NSCLC): results of a prospective randomized study. Lung Cancer. 2007;55(2):173-80.

  42. Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2 (Stage IIIA) Non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg. 2006; 131:1229-35.

  43. Sakao Y, Okumura S, Mun M, Uehara H, Ishikawa Y, Nakagawa K. Prognostic heterogeneity in multilevel N2 non-small-cell lung cancer patients: importance of lymphadenopathy and occult intrapulmonary metastases. Ann Thorac Surg. 2010; 89:1060-3.

  44. Iwasaki A, Shirakusa T, Miyoshi T, Hamada T, Enatsu S, Maekawa S, et al. Prognostic significance of subcarinal station in non-small cell lung cancer with T1-3 N2 disease. Thorac Cardiovasc Surg. 2006;54(1):42-6.

  45. Chen QK, Ding JA, Gao W, Zhu YM. [Skip metastasis to mediastinal lymph nodes: clinical significance and prognosis in stage III non-small cell lung cancer]. Zhonghua Jie He He Hu Xi Za Zhi. 2005;28(7):472-4.

  46. Inoue M, Sawabata N, Takeda S, Ohta M, Ohno Y, Maeda H. Results of surgical intervention for p-stage IIIA (N2) non- small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe. J Thorac Cardiovasc Surg. 2004;127:1100-6.

  47. Adelstein DJ, Rice TW, Rybicki LA, Greskovich JF. Accelerated hyperfractionated radiation, concurrent paclitaxel/cisplatin chemotherapy and surgery for stage III non-small cell lung cancer. Lung Cancer 2002;36(2):167-174.

  48. Ahn YC, Park K, Kim KM. Preoperative concurrent chemoradiotherapy for stage IIIA non-small cell lung cancer. Acta Oncol 2001;40(5):588-92.

  49. Andre F, Grunenwald D, Pignon JP. Survival of patients with resected N2 non-small cell lung cancer (NSCLC): heterogeneity of prognosis and evidences for a subclassification and implications (Abstract). J Clin Oncol. 2000;18:2981-9.

  50. Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Matsuoka H. Prognosis of completely resected pN2 non-small cell lung carcinomas: what is the signi?cant node that affects survival? J Thorac Cardiovasc Surg. 1999;118:270-5.

  51. Nakanishi R, Osaki T, Nakanishi K. Treatment Strategy for patients with surgically discovered N2 stage IIIA non- small cell lung cancer. Ann Thorac Surg 1997;64:342-8.

  52. Patterson GA, Piazza D, Pearson FG, Tood TR. Signi?cance of metastatic disease in subaortic lymph nodes. Ann Thorac Surg. 1987;43:155-9.

  53. Martini N, Kris MG, Flehinger BJ, Gralla RJ. Preoperative chemotherapy for stage IIIA (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg. 1993;55(6):1365-73-4.

  54. Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IIIA non-small-cell lung cancer from N2 disease: Who returns to the surgical are as and who survives. Ann Thorac Surg. 2008; 86:912-20.

  55. Naruke T, Goya T, Tsuchiya R. Prognosis and survival in resected lung carcinoma based on the new international staging system. The Journal of Thorac and Cardiovasc Surgery. 1988;96(3):440-7.

  56. Riquet M, Arame A, Foucalt C, Le Pimpec Barthes F, Prognostic classifications of lymph node involvement in lung cancer and current International Association for the Study of Lung Cancer descriptive classification in zones. Interract Cardiovasc Thorac Surg 2010;11(3):260-4.

  57. International Union Against Cancer. TNM Classification of Malignant Tumors. 7th ed. Hoboken, NJ: Wiley-Blackwell;2009.

  58. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009.

  59. De Leyn P, Lardinois D, Van Schil PE, Rami-Porta R, Passlick B, Zielinski M, et al. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg. 2007; 32(1):1-8.

  60. García Rodríguez ME. Estadificación y valoración mediastínica del cáncer del pulmón. Rev Cubana Cir; 49(4):82-93.Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-74932010000400012&lng=es

  61. Koshy M, Goloubeva O, Suntharalingam M. Impact of Neoadjuvant Radiation on Survival in Stage III Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2011;79(5):1388-94.

  62. Rusch VW, Albain KS, Crowley JJ, Rice TW, Lonchyna V, McKenna Jr R, et al. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg 1993;105:97-106.

  63. Kim KJ, Ahn YC, Lim do H, Han J, Park K, Park JO, et al. Analyses on prognostic factors following tri-modality therapy for stage IIIa non-small cell lung cancer. Lung Cancer. 2007;55(3):329-36.

  64. Ohtsuka T, Nomori H, Ebihara A, Watanabe K, Kaji M, Naruke T, et al. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2006;12(2):89-94.

  65. Sánchez de Cos J. Estadificación y pronóstico molecular del cáncer de pulmón. Arch Bronconeumol 2011;47(11):539-40.

  66. Cabanyes Candela S, Detterbeck FC. A Systematic Review of Restaging After Induction Therapy for Stage IIIa Lung Cancer Prediction of Pathologic Stage. J Thorac Oncol. 2010;5:389-98.

  67. Mathisen DJ, Wain JC, Wright C, Choi N, Carey R, Hilgenberg A, et al. Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1996;111(1):123-31-3.

  68. López-Encuentra A, García R, Rivas JJ, Rodríguez J, Torres J, Varela G. Comparison between clinical and pathologic staging in 2,994 cases of lung cancer. Ann Thorac Surg. 200579:974-9.

  69. Rosell R, Gómez-Codina J, Camps C, Maestre J, Padille J, Canto A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non- small-cell lung cancer. N Engl J Med. 1994;330:153-8.

  70. Lardinois D. Pre- and intra-operative mediastinal staging in Non-small-cell lung cancer. Swiss Med Wkly. 2011;141:w13168.

  71. Tanner NT, Gomez M, Rainwater C, Nietert PJ, Simon GR, Green MR, et al. Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selection. J Thorac Oncol. 2012 Feb;7(2):365-9.

  72. Cerfolio RJ, Bryant AS, Jones VL, Cerfolio RM. Pulmonary resection after concurrent chemotherapy and high-dose (69Gy) radiation for non-small cell lung cancer is safe and may provide increased survival. Eur J Cardiothorac Surg. 2009. Apr;35(4):718-23.




2020     |     www.medigraphic.com